Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HOMA-PULSE: Assessment of Glucose Metabolism and Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation

NCT07551947 is registered in ClinicalTrials.gov with Nemocnice AGEL Trinec-Podlesi a.s. as lead sponsor.

NCT NCT07551947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07551947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HOMA-PULSE: Assessment of Glucose Metabolism and Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation
Lead sponsor
Nemocnice AGEL Trinec-Podlesi a.s.
Phase
Observational
Overall status
Enrolling by invitation
Start date
April 1, 2026
Completion date
December 31, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

artificial intelligence, atrial fibrillation, catheter ablation, insulin resistance